Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Journal of Clinical Oncology
Personen und Körperschaften: Valpione, Sara, Carlino, Matteo S., Mangana, Joanna, Mooradian, Meghan, McArthur, Grant A., Schadendorf, Dirk, Hauschild, Axel, Long, Georgina V., Arance, Ana M., Ascierto, Paolo Antonio, Maio, Michele, De Rosa, Francesco, Larkin, James M. G., Park, John J., Goldinger, Simone M., Flaherty, Keith, Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael, Lorigan, Paul
In: Journal of Clinical Oncology, 35, 2017, 15_suppl, S. 9512-9512
Format: E-Article
Sprache: Englisch
veröffentlicht:
American Society of Clinical Oncology (ASCO)
Schlagwörter:
Cancer Research
Oncology
Details
Zusammenfassung: <jats:p> 9512 </jats:p><jats:p> Background: Most patients treated with BRAF inhibitors (BRAFi) +/- MEK inhibitors (MEKi) eventually progress on treatment. Along with genetic acquired resistance, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse outcomes for patients (pts) retreated with BRAF-directed therapy. Methods: 116 pts who received BRAFi based therapy and, after a break, were re-challenged with BRAFi +/- MEKi treated at 14 centres in Europe, US, and Australia were analysed for progression free survival (PFS) and response rate (RR), as well as factors predicting overall survival (OS) (demographics, disease stage, treatment, LDH level, duration of first BRAFi treatment, reason for first BRAFi discontinuation and interval between BRAFi stop and re-challenge). Multivariate Cox regression, regression trees and Kaplan Meier method were used. Results: Median duration of 1<jats:sup>st</jats:sup> BRAFi +/- MEKi treatment was 9.4 months (mts) and 7.7 mts for the subsequent treatment after discontinuation (immunotherapy 72%, other 17 %, drug holiday 11%). Brain metastases were present in 51 pts (44%). RR to re-challenge with BRAFi +/- MEKi was 43%: complete response (CR) 3%, partial response (PR) 39%, stable disease 24% and progressive disease (PD) 30%, 4% missing. Of 80 pts who previously discontinued BRAFi for PD, 31 (39%) responded (30 PR and 1 CR). Median OS from retreatment was 9.8 mts. Independent prognostic factors for survival at re-challenge included number of metastatic sites (HR = 1.32 for each additional organ with metastases, p &lt; .001), LDH (HR = 1.37 for each multiple of the upper normal limit, p &lt; .001), while combination of BRAFi+MEKi conferred a better prognosis vs BRAFi alone (HR = 0.5, p = .006). Pts with &lt; 3 metastatic sites treated with BRAFi and MEKi had a better survival (median OS not reached) and pts with ≥ 3 metastatic sites and raised LDH treated with BRAFi alone had the worse outcome (median OS 4 mts). Number of metastatic sites (HR = 1.44, p &lt; .001) and combination of BRAFi and MEKi (HR = 0.45, p &lt; .001) were independent prognostic factors for PFS (median 5.0 mts). Conclusions: Re-challenge with BRAFi +/- MEKi induces a clinically significant response and should be considered for selected cases. </jats:p>
Umfang: 9512-9512
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2017.35.15_suppl.9512